“Since there are treatments for SMA, we know we can stop this progressive disease. Her image changes. It becomes a chronic disease, not a fatal one. We are proud of it. We hope for further successes and further therapies - said Dorota Raczek, president of the SMA Foundation, in an interview with Medexpress.
How would you summarize the implementation of the spinal muscular atrophy drug program for nusinersen over the last few years?
The implementation of this program was very quick. In the first year, we saw a very large increase in the number of patients who were included in it. Children were the priority. In each subsequent year, patients were implemented proportionally. We now have over 850 patients treated under the drug program.
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
If you already have an account, please log in
